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Abstract 
Smart drug delivery systems are required for the site-specific drug targeting to enhance the therapeutic 
efficiency of a drug. Resveratrol (RV) is a polyphenolic compound with anti-cancer activity. However, its 
poor aqueous solubility and non-selectivity are the major challenges for its employment in cancer 
therapy. In this work, we present the synthesis of RV-loaded glutathione responsive cyclodextrin 
nanosponges (RV-GSH-NSs) to improve the therapeutic efficiency and selective delivery of RV. The drug 
loading and encapsulation efficiency were 16.12% and 80.64%, respectively. The in vitro release profile 
confirmed that RV release was enhanced in response to external glutathione (GSH). Nude NSs were not 
toxic per se to human fibroblasts when administered for up to 72 h at the highest dose. Cell internalization 
studies confirmed that RV-GSH-NSs were preferentially up-taken by tumor cells compared to 
non-tumorigenic cells. Accordingly, RV showed selective toxicity to cancer cells compared to normal 
cells. GSH depletion by buthionine sulfoximine, a potent inhibitor of its synthesis, reflected in a significant 
decrease of the NSs accumulation, and consequently resulted in a drastic reduction of RV-mediated toxic 
effects in cancer cells. These findings demonstrate that GSH- responsive NSs represent an effective 
delivery system for targeting cancer cells by harnessing the differential tumor characteristics in terms of 
redox status in parallel with the limitation of side effects toward normal cells. 
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Introduction 
Breast and ovarian cancers are among the most 
frequently diagnosed and deadly gynecological 
cancers [1]. Chemotherapy, in association or not with 
surgery, is the most common therapeutic option for 
the treatment of these cancers. However, 
chemotherapeutic drugs are associated with several 
drawbacks such as low selectivity, low aqueous 
solubility, and low bioavailability [2, 3]. To overcome 
these challenges new therapeutic approaches are 
required, and smart drug delivery systems could 
represent a valuable tool. Resveratrol (RV) is a natural 
polyphenolic compound that can be obtained from 
various natural sources such as grapes, peanuts, 
mulberries, and Japanese knotweed [4]. RV provides a 
wide range of preventive and therapeutic effects 
against different types of cancer, as testified by the 
increasing number of ongoing clinical trials that are 
screening its effectiveness as anti-cancer [5]. As a 
matter of fact, RV has shown the ability to reduce 
tumor growth in vivo [6-8], and this anti-cancer 
activity has been linked to epigenetic mechanisms [9, 
10], autophagy [11-13], apoptosis [14, 15], induction of 
senescence [16, 17], interruption of the crosstalk 
between cancer cells and stromal fibroblasts [18], 
among others. However, low aqueous solubility, 
chemical instability, and non-selectivity are the major 
limitations for the employment of RV in cancer 








formulations with increased bioavailability 
specifically at the tumor site are needed. 
Smart drug delivery systems such as liposomes, 
dendrimers, stimuli-responsive polymeric 
nanoparticles, and micelles are extensively used to 
improve the safety and efficacy of the administered 
drug molecules [22, 23]. Cyclodextrin-based 
nanocarriers can form inclusion complexes with 
therapeutics molecules increasing their aqueous 
solubility and stability, and therefore represent also a 
valid system for drug delivery [24, 25]. Cyclodextrin 
nanosponges (NSs) are hyper-crosslinked polymers 
featuring high drug loading and solubilization 
efficiency. Anti-cancer drugs used as the guest 
molecules in NSs include paclitaxel [26], 
camptothecin [27], erlotinib [28], oxy-resveratrol [29], 
and tamoxifen [30]. However, non-selectivity of the 
developed formulation still limits the pharmacologic 
efficacy and remains a challenging task. 
Stimuli-responsive drug delivery systems offer 
the advantage of site-specific drug delivery and 
release in response to tumor chemical characteristics 
such as pH, intracellular enzymes, and redox gradient 
[31-33]. For instance, the concentration of glutathione 
(GSH) is higher in tumor cells (0.5-10 mM) compared 
to the normal cells (2-20 µM) [34]. This significant 
difference in terms of GSH concentration has prompt 
the design of GSH-responsive nanocarriers for tumor- 
targeted delivery of the drugs [35]. The presence of 
disulfide groups in the NSs promotes the release of 
drug molecules in response to the intracellular GSH 
concentrations. Daga and co-workers demonstrated 
the in vitro anti-cancer efficiency of doxorubicin 
(DOX)-loaded GSH-responsive NSs in different 
cancer cells [36]. Moreover, in vivo studies suggested a 
prolonged plasma circulation time of the DOX-GSH- 
NSs compared to free DOX [36]. GSH-responsive 
cyclodextrin NSs loaded with anticancer drug have 
been shown to kill preferentially cancer cells highly 
expressing GSH [37]. 
In the present study, we developed the GSH- 
responsive NSs (GSH-NSs) for the tumor-specific 
delivery of RV. We validated in vitro the selectivity of 
the targeting of our delivery system by demonstrating 
the preferential uptake of RV-GSH-NSs in cancer cells 
rather than in normal cells. We prove that this 
differential internalization reflects in a selective 
cytotoxicity towards cancer cells highly expressing 
GSH, as indicated by the fact that GSH depletion 
abrogates RV-GSH-NSs toxicity. Further, we show 
that chronic administration of nude GSH-NSs at high 
concentration is not toxic to normal fibroblasts. 
Materials and Methods 
The β-cyclodextrin (β-CD) was a kind gift from 
Roquette Italia (Cassano Spinola, Italy). Resveratrol, 
pyromellitic dianhydride, 2-hydroxyethyl disulfide, 
and glutathione were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Unless otherwise specified, all 
other chemicals were of analytical grade. 
Synthesis of the GSH-NSs 
Glutathione-responsive β-CD nanosponges 
(GSH-NSs) were prepared by a method developed by 
our group earlier [38]. Briefly, 2.0 g (1.76 mmol) of 
anhydrous β-CD was dissolved in 8 mL of DMSO 
with continuous stirring until a clear solution is 
formed. Later, 0.200 g (1.29 mmol) of 2-hydroxyethyl 
disulfide and 2.0 mL (14.35 mmol) of triethylamine 
was added as a catalyst. Finally, 5.5 g (24.48 mmol) of 
pyromellitic dianhydride was added to the solution 
with vigorous stirring to carry out the reaction. 
Gel-like mass was obtained within a few minutes 
which was incubated for the next 24 hours at room 
temperature to complete the reaction. At the end of 
the reaction, a solid monolith block of GSH-NSs was 
crushed to obtain a coarse powder followed by 
extensive washing with water and acetone. The 
prepared GSH-NSs were purified by Soxhlet 
extraction with acetone for a period of approximately 
24 hours and air-dried at room temperature. GSH-NSs 
were kept in a desiccator for further use. The sulfur 
content within the GHS-NSs was determined by 
elemental analysis (Thermo Electron Corporation 
Flash EA 1112 series CHNS-O Analyzer) using an 
equal amount of V2O5 as a catalyst (2.5 mg). 
Preparation of RV and Coumarin-6 loaded 
GSH-NSs 
Before performing drug loading, 
nanosuspension of GSH-NSs (10 mg/mL in water or 
saline) was prepared by high shear homogenizer 
(Ultraturrax®, IKA, Konigswinter, Germany) for 10-15 
min at 24,000 rpm followed by high-pressure 
homogenization (HPH) for 1.5 hours at a back 
pressure of 500 bar using an EmulsiFlex C5 
instrument (Emulsiflex C5, Avestin, USA). Later, 
nanosuspension was dialyzed for a few minutes. 
RV-loaded GSH-NSs were prepared by adding 
RV in a different weight ratio of 1:2, 1:4, and, 1:6 
(w/w; drug: nanosponge) in a nanosuspension of 
GSH-NSs (10 mg/mL). Later, samples were sonicated 
for 20 minutes followed by continuous stirring for 24 
hours in dark. Samples were subjected to mild 
centrifugation and supernatant was collected 
followed by dialysis in water for a few minutes to 
remove the unloaded drug. RV-loaded GSH-NSs 
were freeze-dried and stored in a desiccator for 
further characterization. Fluorescent NSs were 
prepared in a similar manner by taking NS 




suspension (10 mg/mL) in saline with 0.1 mg/mL 
coumarin-6 (C-6). 
Quantitative determination of the RV 
The concentration of RV was quantified using an 
HPLC system (PerkinElmer, Waltham, USA) 
equipped with a UV detector (Flexar UV/Vis LC 
spectrophotometer). We used a reversed phase 
Phenomenex C18 analytical column (4.6 mm × 250 
mm, 5 µm) with a mobile phase consisted acetic acid 
in methanol (0.5 %, v/v) and water (52:48, v/v). The 
degassed mobile phase was passed through the 
column with a flow rate and injection volume of 1 
mL/min and 20 µL, respectively at an absorption 
maxima of 305 nm and retention time of 6.9 minutes 
[39]. A calibration curve was recorded at the 
concentration of 2-10 µg/mL and a good correlation 
coefficient of 0.9997 was observed. 
Determination of the drug loading and 
encapsulation efficiency 
Freeze-dried RV-GSH-NSs were suspended into 
a vial containing 2 mL of methanol and sonicated for 2 
hours. Later, it was centrifuged, and the supernatant 
was analyzed after appropriate dilution with the 
mobile phase. 
The following equation was used to determine 
drug loading and encapsulation efficiency: 
Drug Loading (% DL) = [Entrapped RV/Weight of 
GSH-NSs]*100 
Encapsulation Efficiency (% EE) = [Entrapped 
RV/Total RV]*100 
Particle size, polydispersity index (PDI), and 
zeta potential of RV-GSH-NSs 
The mean particle size and polydispersity index 
of blank GSH-NSs, RVGSH-NSs, and C-6 loaded 
GSH-NSs were determined by dynamic light 
scattering with the help of Malvern Zetasizer Nano 
(Worcestershire, UK) after suitable dilution with 
HPLC grade water. An additional electrode was 
placed inside the zetasizer to determine the zeta 
potential of all the samples by measuring the 
electrophoretic mobility at room temperature. 
Thermal analysis 
Differential scanning calorimetry (DSC) 
measurements were performed using a TA 
instruments Q200 DSC (New Castle, DE, USA) at a 
temperature range of 30-300 °C with a scanning rate of 
10 °C/min. Freeze-dried samples (2-3 mg) were 
placed inside the standard aluminum pan and an 
empty pan was used as a standard. All the samples 
were analyzed under a nitrogen purge of 50 mL/min. 
Fourier Transform Infrared Spectroscopy 
(FTIR) 
The FTIR spectra of RV, Blank GSH-NSs, and 
RV-loaded GSH-NSs were obtained by PerkinElmer 
100 FTIR to determine the interaction of RV with 
GSH-NSs. The spectra were recorded on attenuated 
total reflectance (ATR) assembly in a range of 
4000-650 cm-1 at a resolution of 4 cm-1 and analyzed on 
spectrum software. 
Powder X-ray diffraction studies 
Malvern Panalytical X’Pert diffractometer 
(Worcestershire, UK) was used to record the 
diffraction pattern of RV, Blank GSH-NSs, and 
RV-loaded GSH-NSs. Cu Kα1 was employed as a 
radiation source and data acquisition was carried out 
at the diffraction angle of 5-45° 2θ at a step size of 
0.015°. 
Determination of the morphology 
Transmission electron microscopy (TEM) and 
field emission scanning electron microscopy 
(FE-SEM) studies were performed to determine the 
particle shape and size. Aqueous nanosuspension of 
samples were placed on the aluminum stub with the 
help of a bio-adhesive carbon tape and air-dried 
followed by sputter-coating with gold to analyze on 
FE-SEM (ZEISS supra 40, Oberkochen, Germany). For 
TEM (JEOL JEM 3010, MA, USA) studies aqueous 
nanosuspension of samples were sprayed on Formvar 
coated copper grid and air-dried before image 
acquisition. 
In vitro drug release 
In vitro release study of RV from the GSH-NSs 
was carried out in phosphate buffer pH 7.4 by 
membrane diffusion method using a dialysis 
membrane cut off size of 12 kDa. A known quantity of 
RV-GSH-NSs (10 mg) was suspended in 1 mL of 
phosphate buffer solution. The suspension was filled 
in the dialysis bag and placed inside a vial containing 
10 mL of a phosphate buffer solution with continuous 
stirring of 50 rpm at 37 ± 0.5 °C. The effect of GSH on 
the drug release was also studied by adding 10 mM 
GSH and 20 mM GSH in the dissolution media. The 
aliquots (1 mL) were withdrawn at different time 
intervals and replaced with the same amount of 
respective fresh phosphate buffer. Later, all the 
samples were filtered with a 0.4 µm syringe filter and 
analyzed on HPLC after suitable dilution with the 
mobile phase. 
Cell culture 
All cell lines were obtained from ATCC 
(Manassas, Virginia, USA) and maintained under 




standard culture conditions (37°C, 5% CO2). SKOV3 
and OVCAR3 human ovarian cancer cell lines were 
cultured in RPMI 1640 medium supplemented with 
10% heat-inactivated fetal bovine serum (FBS), 1% 
Glutamine and 1% Penicillin/Streptomycin solution. 
MDAMB231 human triple-negative breast cancer cells 
and human fibroblasts were cultured in DMEM 
medium supplemented with 10% heat-inactivated 
fetal bovine serum (FBS), 1% Glutamine and 1% 
Penicillin/Streptomycin solution. MCF10A human 
mammary epithelial cell line was cultured in 
DMEM-F12 (1:1) medium supplemented with 15% 
heat-inactivated horse serum, 1% Glutamine and 1% 
Penicillin/Streptomycin solution, 500 µg/ml 
hydrocortisone, 100 ng/ml cholera toxin, 10 µg/ml 
insulin and 20 ng/ml EGF. 
Intracellular accumulation of the GSH-NSs 
Cells were plated on sterile coverslips and then 
incubated with C-6-loaded GSH-NSs for the indicated 
time points. Coverslips were promptly observed 
under the fluorescence microscope. To confirm that 
cell uptake and intracellular accumulation were 
regulated by intracellular glutathione, the cells were 
depleted of intracellular GSH by pre-treatment for 16 
h with buthionine sulfoximine (BSO; cod. 
004CA14484, Cayman), a potent inhibitor of the 
enzyme gamma-glutamyl-cysteine synthetase. BSO 
was dissolved in sterile water and used at 1 mM final 
concentration. 
Cell tracker staining 
Cells plated on sterile coverslips and treated 
with the RV-GSH-NSs as indicated were labeled with 
the fluorescent dye Cell Tracker (Cell Tracker Blue- 
CMAC 7-amino-4-chloromethylcoumarin; incubation 
for 30 min in serum-free media at 37 °C followed by 
additional 30 min in complete media at 37 °C; cod. 
C2110, Life Technologies) as previously reported [40]. 
At the end of treatment, fluorescence stained 
coverslips were promptly observed under the 
fluorescence microscope. 
Propidium iodide staining 
Cells plated on sterile coverslips were treated as 
indicated. Necrotic cells were detected by using 0.2 
μg/ml propidium iodide (PI; incubation for 10 min in 
the dark at 37 °C; cod. P4170, Sigma Aldrich). At the 
end of treatment, fluorescence stained coverslips were 
promptly observed under the fluorescence 
microscope. 
Imaging acquisition and analysis 
Fluorescence images were acquired at the 
multi-channel fluorescence microscope (Leica 
Microsystems, Wetzlar, Germany; DMI6000). For each 
experimental condition, at least three slides were 
prepared in separate experiments and five to ten 
microscopic fields randomly chosen were imaged by 
two independent investigators unaware of the 
treatment. At least 100 to 150 cells were considered in 
total. Quantification of fluorescence intensity was 
performed with the software ImageJ. Representative 
images of selected fields are shown. 
Western blotting 
Cells were seeded in petri dishes at the cell 
density of 40,000-50,000 cell/cm2 and cultured up to 
approximately 80% of confluence. Cells were washed 
once with PBS 1X and harvested with lysis buffer 
containing 0.2% NaDOC and supplemented with 
protease inhibitor cocktail and phosphatases 
inhibitors (50 mM NaF, 1 mM Na3VO4). Bradford 
assay was used to measure the protein content. Equal 
amounts of cell homogenates (30 μg) were denatured 
at 95°C for 10 min, resolved by SDS-PAGE and 
thereafter blotted onto PVDF membrane. For 
detection of GSH by western blotting, we performed a 
20% PAGE under non-reducing conditions (avoiding 
the use of SDS and of DTT, as recommended by the 
manufacturer). The membranes were blocked with 5% 
non-fat dry milk + 0.2% Tween for 1 hour at room 
temperature and thereafter incubated with primary 
antibodies overnight at 4°C. The following day, the 
membranes were washed and incubated with the 
secondary antibody (Goat anti-mouse (cod. 170-6516) 
or Goat anti-rabbit (cod. 170-6515); Bio-Rad) for 1 
hour at room temperature. The membranes were 
washed, and the bands were detected by using 
Enhanced Chemiluminescence reagents (ECL; cod. 
NEL105001EA; PerkinElmer) and imaged with the 
VersaDOC Imaging System. For loading control, the 
membranes were re-probed with housekeeping 
markers (i.e. β-tubulin, β-actin, GAPDH). The 
intensity of the bands was estimated by densitometry 
using Quantity One software. 
Antibodies 
The following antibodies were used: mouse 
anti-β-actin (1:2000, cod. A5441, Sigma Aldrich), 
rabbit anti-GAPDH (1:1000, cod. G9545, Sigma 
Aldrich). mouse anti-caspase 8 (1:500, cod. 9746, Cell 
Signaling), mouse anti-β-tubulin (1:1000, cod. T5201, 
Sigma Aldrich), mouse anti-glutathione (1:1000, cod. 
MA17620, Life Technologies), mouse anti-caveolin-1 
(1:1000, cod. 610406, BD). 
Statistical analysis 
Statistical analysis was performed with 
GraphPad Prism 5.0 software. Bonferroni’s multiple 
comparison test after one-way or two-way ANOVA 
analysis (unpaired, two-tailed) were employed. 




Significance was considered as follow: **** p< 0.0001; 
***p < 0.001; **p < 0.01; *p < 0.05. All data are reported 
as average ± S.D. 
Results 
Physicochemical Characterization of the 
RV-GSH-NSs 
GSH-responsive β-CD-NSs were prepared from 
pyromellitic dianhydride and 2-hydroxyethyl 
disulfide as the crosslinkers. A schematic of the 
structure of the GSH-NSs is shown in Supplementary 
Figure S1. After complete purification, we first 
performed an elemental analysis to determine the 
presence of sulfur in the blank GSH-NSs. The carbon 
and hydrogen contents were 54.42% and 5.33%, 
respectively as confirmed by CHNS analysis. 
Moreover, the sulfur content in the GSH-NSs was 
0.75%. However, the sulfur content was lower than 
the theoretical value of 0.97%. The lower sulfur 
content could be attributed to the low reactivity of 
2-hydroxyethyl disulfide as a crosslinking agent 
compared to β-CD. Furthermore, elemental analysis 
results are in agreement with the previously reported 
data [38]. The solubilization of RV in the presence of 
GSH-NSs was studied to confirm the enhancement in 
the aqueous solubility which showed more than 
four-fold higher solubilization (201 µg/mL) in water 
compared to free RV (46 µg/mL). The increase in the 
solubility could be attributed to the presence of 
multiple cavities of the CDs in the polymeric matrix of 
the GSH-NSs. The loading of RV with GSH-NSs was 
carried out by taking different weight ratios of 1:2, 1:4, 
and 1:6 (w/w; RV-GSH-NSs), respectively. The RV 
loading was 9.95% at 1:2 w/w which increased 
significantly to 16.12% at 1:4 w/w. However, RV 
loading decreased to 13.72% at 1:6 w/w, possibly due 
to the saturation of the RV into the GSH-NSs. As per 
the drug loading data, RV-GSH-NSs (1:4 w/w) were 
chosen to carry out further studies. In Supplementary 
Table 1, the particle size, polydispersity index (PDI), 
zeta potential, and encapsulation efficiency of 
GSH-NSs formulations are reported. The particle size 
of blank GSH-NSs was less than 200 nm, and zeta 
potential was high enough to ensure the physical 
stability of nano-formulation in order to avoid the 
agglomeration of the colloidal NS particles. The 
physical interaction of RV with GSH-NSs was 
evaluated by FTIR, DSC, and PXRD studies. The FTIR 
spectra of blank GSH-NSs, RV, and RV-GSH-NSs are 
shown in Supplementary Figure S2(A). The FTIR 
spectrum of RV showed characteristic peaks at 3210 
cm-1 due to stretching of the O-H group, followed by 
C-H stretching of phenyl ring at 3017 cm-1, C=C 
stretching at 1608 cm-1, and O-H bending at 1325 cm-1. 
It was also observed that RV encapsulation within 
GSH-NSs led to the change and shift in the 
characteristic vibrations of the RV. This change in the 
FTIR spectrum of RV could be due to the interaction 
of the drug with GSH-NSs. 
DSC studies were performed to confirm the 
encapsulation of the RV within the GSH-NSs. No 
endothermic transitions were observed with blank 
GSH-NSs which confirm the stability of the NSs at the 
tested temperature range as shown in Supplementary 
Figure S2(B). However, RV showed an endothermic 
peak at 268.32 °C, which corresponds to its melting 
point. The endothermic melting peak RV was masked 
in case of RV-GSH-NSs which could be attributed to 
the encapsulation and subsequent dispersion in the 
molecular state thus unable to crystallize. 
Supplementary Figure S2(C) represents the 
diffraction pattern of blank GSH-NSs, RV, and 
RV-GSH-NSs, respectively. Diffractogram of RV 
showed characteristic diffraction peaks at a 2θ angle 
of 6.59, 16.40, 19.22, 20.36, 22.40, 23.64, 24.15, and 28.35 
which confirms its crystalline nature. However, 
RV-GSH-NSs and blank GSH-NSs do not exhibit any 
intense peak similar in their respective PXRD pattern. 
The loss in the crystallinity of the RV confirmed the 
molecular dispersion into the GSH-NSs due to the 
successful encapsulation within the nanosponge 
matrix. These findings were consistent with 
previously reported data related to RV and other NSs 
[26, 27, 41]. 
The morphology and size of the RV-GSH-NSs 
were determined by TEM and FE-ESM as shown in 
Supplementary Figure S2(D). TEM and FE-SEM 
images of RVGSH-NSs confirmed that the particles 
were uniform and in the nanoscale range. The particle 
size obtained with TEM and FE-SEM were also in 
agreement with the DLS results (180-200 nm). 
In vitro release profile of RV from GSH-NSs 
The in vitro release profile of RV-GSH-NSs was 
investigated with and without GSH as shown in the 
Figure 1. It was observed that a slow and consistent 
release of RV was obtained in the response to external 
GSH concentration with no initial burst effect. 
Moreover, RV-GSH-NSs exhibited higher drug 
release compared to RV alone. After 24 hours, 
RV-GSH-NSs showed almost two-fold higher drug 
release compared to RV alone. A higher release profile 
of RV might be due to the enhanced solubilization 
potential of the GSH-NSs. Furthermore, RV-GSH-NSs 
showed more than five-fold higher drug release 
compared to free RV in the presence of 10 mM GSH 
that was further enhanced to eight-fold with 20 mM 
GSH. This behavior of the GSH-NSs confirmed the 
GSH responsiveness of the NSs. The presence of GSH 




in the release media causes a rapid breakdown of the 
nanocarrier which allows the higher release of RV. 
 
 
Figure 1. The release profile of the RV and RV-loaded-GSH-NSs 
(dissolution medium: Phosphate Buffer pH 7.4 Solution, temperature: 37 ± 0.5 °C, 
rotation speed: 50 rpm). 
 
GSH-NSs preferentially enter in cancer cells 
compared to their benign counterparts 
We addressed whether the responsiveness of 
NSs to GSH reflects in a differential uptake by cancer 
cells and benign cells. For this purpose, we have 
employed normal fibroblasts, two ovarian cancer cell 
models (OVCAR3 and SKOV3 cells) differing in the 
genetic background, and a breast cancer model 
(MDAMB231 cells) and its non-tumorigenic 
counterpart (MCF10A cells). As shown in Figure 2, we 
employed four concentrations of GSH-NSs (ranging 
from 10 up to 200 µM) at three different time-points 
(30 minutes, 2 hours and 24 hours). 
To test the internalization of RV-GSH-NSs, we 
employed C-6-loaded GSH-NSs that have intrinsic 
green fluorescence and shares with the RV-GSH-NSs 
the same methods of synthesis and the same 
dimensions. The quantification of the internalization 
rate in the different cell models is reported in 
Supplementary Figure S3. Our data show that 
OVCAR3 cells record the highest internalization rate 
at each time point considered, followed by 
MDAMB231 cells, which exhibit an uptake capacity 
about 25% less than OVCAR3 cells. Moreover, we 
noticed that MDAMB231 cells showed a decrease of 
C-6-GSH-NSs accumulation rate after 24 hours, 
possibly due to extrusion. Further investigations are 
needed to prove this speculation. 
On the other hand, we found that fibroblasts 
internalize C-6-GSH-NSs about 4-times less than 
OVCAR3 cells and 3-times less than MDAMB231 
cells. Likewise, MCF10A cells show an uptake 
efficiency about 10-times less compared to their 
tumorigenic counterpart. These findings confirm that 
on average the capability of internalization and 
accumulation of GSH-NSs of the cancer cells is greater 
than the one of normal cells. Surprisingly, we 
observed that SKOV3 cells were not able to internalize 
the GSH-NSs, which accumulated outside the plasma 
membrane. 
Caveolae-mediated endocytosis is one of the 
main routes for nanoparticle’s cellular entry [42, 43, 
44]. We therefore asked whether caveolin-1 
expression could explain the differential 
internalization process of GSH-NSs in the cell lines 
tested. The western blotting shown in Figure 3A 
suggests that GSH-NSs uptake is not dependent on 
caveolin-1-mediated endocytosis since OVCAR3 cells 
do not express this protein and yet can internalize the 
GSH-NSs, while SKOV3 cells that express caveolin-1 
cannot. 
GSH-NSs can be internalized and take 
advantage of disulfide bridges, which allow the 
release of the drug in the presence of high GSH 
concentration [36]. Next, we validated that 
intracellular distribution and selective NSs delivery 
rely on the differences in the content of glutathione in 
the cell models used. As shown in Figure 3B, we 
found that OVCAR3 cells displayed the highest GSH 
content, followed by MDAMB231 and fibroblasts, and 
this was paralleled by the intracellular accumulation 
of NSs. SKOV3 cells failed to uptake the GSH-NSs 
despite exhibiting a GSH content similar to that in 
fibroblasts, suggesting that these cells may be 
deficient in some key factors involved in the 
mechanism of internalization of this particular 
material. On the other hand, MCF10A cells exhibited a 
modest GSH concentration, as expected for a 
non-tumorigenic cellular context. Thus, except for 
SKOV3 cells, the intracellular distribution profiles of 
β-CD-NSs observed above reflect their dependence on 
intracellular GSH content, which parallels the 
malignant phenotype. 
Resveratrol-mediated toxicity reflects the 
differential internalization of GSH-NSs in 
tumor cells 
First, we tested the potential toxicity of nude 
GSH-NSs toward normal human fibroblasts. The cells 
were exposed to the highest concentration and for up 
to 72 hours. Toxicity was imaged using Cell Tracker 
blue staining, which monitors mitochondrial 
functionality, and Propidium iodide, which labels the 
necrotic cells. As shown in Figure 4, no toxicity was 
observed when the fibroblasts were incubated with 
one single dose for 72 hours (panel A) nor when they 
were administered with three doses every 24 hours 
(panel B). 





Figure 2. GSH-NSs preferentially enter and accumulate in cancer cells compared to normal cells. Cells were plated on sterile coverslips and then incubated with 
increasing concentrations of C-6-GSH-NSs for the indicate time points. C-6-GSH-NSs exhibit an intrinsic green fluorescence and share with the RV-GSH-NSs the same methods 
of synthesis and the same dimensions. So, internalization and intracellular distribution of C-6-GSH-NSs can be assumed similar to those of RV-GSH-NSs. Cell internalization 
studies were performed on normal fibroblasts (A), on two ovarian cancer models, OVCAR3 cells (B) and SKOV3 cells (C), on a non-tumorigenic breast model, MCF10A (D) 
and a breast cancer cell line, MDAMB231 (E). 





Figure 3. GSH-NSs uptake is guided by intracellular GSH content. (A) Western blotting showing the expression of caveolin-1. For loading control, the membranes 
were re-probed with β-Tubulin. Graph representing the densitometric analysis shown as average (A.U., arbitrary units) ±SD. (B) Western blotting to assess intracellular GSH 
content in cell models. For loading control, the membranes were re-probed with β-Tubulin. Graphs representing the densitometric analysis of three independent experiments 
are shown. Data are presented as average (A.U., arbitrary units) ±SD. Significance was considered as follows: *p < 0.05. 
 
Next, we tested whether the delivery of RV by 
GSH-NSs effectively causes toxicity preferentially in 
tumor cells. The cells were exposed to two different 
concentrations of RV- GSH-NSs (100 and 200 µM) for 
24 and 48 hours. Data show no significant difference 
in cell viability, as imaged by Cell Tracker, in 
fibroblasts and in benign epithelial MCF10A cells 
(Figure 5A), and in SKOV3 cells (data shown in 
Supplementary Figure S4), even when treated with 
the highest concentration for 48 hours. 
In contrast, OVCAR3 and MDAMB231 cells 
show a dose-dependent reduction in cell viability, as 
indicated by the decreased Cell Tracker fluorescence 
intensity. This effect was more evident and 
anticipated in OVCAR3 compared to MDAMB231 
cells. Taken together, these data show that 
RV-GSH-NSs preferentially affect cell viability in 
tumor cell lines compared to the non-tumoral ones, 
suggesting that the delivery and toxicity is (quite) 
selective for tumor cells expressing GSH at level much 
above the physiological level. 
The selective toxicity of RV-GSH-NSs toward 
cancer cells was further confirmed by propidium 
iodide (PI) staining (Figure 5B). In this case, the 
increase of PI-positive cells (red fluorescent signal) 
indicates that cells undergo necrosis. In line with the 
previous results, cell death in fibroblasts and MCF10A 
cells was negligible, regardless of the time of 
incubation and concentrations of GSH-NSs. A similar 
pattern was observed in SKOV3 cells (data shown in 
Supplementary Figure S4). In contrary, OVCAR3 and 
MDAMB231 cells that express the highest level of 
GSH show a dose-dependent increase in cell death 
upon exposure to RV-GSH-NSs. Again, OVCAR3 cells 
show a higher sensitivity compared to MDAMB231 
cells, consistent with the internalization rate. 
Overall, these data confirm that the differential 
intracellular accumulation of the NSs between the cell 
lines that parallels the GSH content reflects in a 
selective toxic effect. 
To determine whether toxicity resulted from 
apoptosis and/or necroptosis, we carried out a double 
staining with propidium iodide (PI) and annexin 
V-FITC (ANN-V) on living (not fixed) cells. We also 
employed the enzymatic inhibitors Necrostatin-1 
(NEC-1) and ZVAD, that inhibit necroptosis and 
caspase-dependent apoptosis, respectively. As 
positive control to induce cell death in cancer cells, we 
employed the chemotherapeutic agent oxaliplatin 
(OxPt). 
We incubated OVCAR3 and MDAMB231 cells 
with the highest concentration of RV-GSH-NSs (200 
µM) alone or in the presence of the two inhibitors. The 
representative images shown in Figure 6A indicate 
the presence of secondary necrosis (ANN-V/PI 
double positive) in OVCAR3 cells exposed to 
RV-GSH-NSs for 24 hours. Both the inhibitors could 
protect the cells from RV-GSH-NSs, yet to a different 
extent: NEC-1 increased by 3-folds and ZVAD by 
5-folds the number of living (double-negative) cells, 
indicating that both apoptosis and necroptosis 
pathways are involved in the mechanism of toxicity. 





Figure 4. Nude β-CD-GSH-NSs are not toxic for normal fibroblasts. Fibroblasts were plated on sterile coverslips and treated for 72 hours with C6-GSH-NSs 
administered in single dose with no change of the medium (A) or in three doses (every 24 h) by renovating the treatment (B). Cells were labeled with Cell Tracker Blue 
fluorescent dye (left panel) or with Propidium iodide (PI) (right panel). Coverslips were washed and mounted on glasses and imaged immediately at the fluorescent microscope. 
Graphs represent the quantification of fluorescence intensity (INT.DEN. average per cell ± SD) for Cell Tracker staining, while cell death was assessed by counting the percentage 
of PI positive cells and represented in the graphs (% ± SD). Representative images of three independent experiments are shown. 
 
In MDAMB231 cells incubated with RV-GSH- 
NSs for 48 hours about 70% display ANN-V/PI 
double positivity. Again, NEC-1 and ZVAD increased 
the proportion of living cells by 4.5-folds and 
4.0-folds, respectively (Figure 6B). 
To get a further insight on the mechanism of cell 
death, we assessed caspase 8 expression and cleavage 
by western blotting. In line with the previous 
findings, we observed only a slight activation of the 
caspase 8 cascade (Supplementary Figure S5). This 
suggests that RV-GSH-NSs trigger a caspase- 
independent necrotic cell death in parallel with the 
canonical apoptotic mechanism. 
GSH depletion strongly impairs RV-GSH-NSs 
intracellular accumulation in tumor cells 
To finally prove that the targeting promoted by 
GSH-NSs was effectively guided by the intracellular 
concentration of glutathione, we depleted the cells of 
GSH by using buthionine sulfoximine (BSO), an 
inhibitor of gamma-glutamylcysteine synthetase 
(gamma-GCS). 
To assay the efficiency of GSH depletion, we 
assessed GSH levels in OVCAR3 and MDAMB231 
cells after the exposure to BSO for 24 hours. As shown 
in Figure 7A, BSO greatly reduced GSH expression in 
OVCAR3 cells and it completely suppressed GSH 
content in MDAMB231 cells. 
The internalization rates of C-6-GSH-NSs in 
OVCAR3 and MDAMB 231 cells pre-treated or not 
with BSO is shown in Figure 7B-C. Both the cancer 
cells pre-treated with the inhibitor exhibited a 
significant decrease in the NSs intracellular 
accumulation at both concentrations considered (100 
and 200 µM) after 24 hours of incubation. Moreover, 
upon treatment with BSO, the accumulation rate was 
similarly low for the two concentrations tested in both 
the cell models used, suggesting that GSH depletion 




strongly hampered the capability of cancer cells to 
redistribute GSH-NSs in the cytoplasm. The reduced 
intracellular accumulation of GSH-NSs does not result 
from NSs exocytosis and extrusion at late time, since 
the rate of accumulation of NSs in BSO-pre-treated 
cells is very low from the early beginning (30 minutes 
and 2 hours) (data in Supplementary Figure S6). 
 
 
Figure 5. RV-loaded-GSH-NSs selectively affect the cell viability of cancer cells compared to non-tumorigenic ones. Cells were plated on sterile coverslips and 
treated with RV-GSH-NSs for the indicated time points. (A) Cells were labeled with Cell Tracker Blue fluorescent dye. Coverslips were washed and mounted on glasses and 
imaged immediately at the fluorescent microscope. Staining was performed in fibroblasts (24 and 48 hours), OVCAR3 (24 hours), MCF10A (48 hours) and MDAMB231 (48 
hours). Graphs represent the quantification of fluorescence intensity (INT.DEN. average per cell) ± SD. Representative images of three independent experiments are shown. 
Significance was considered as follows: *p < 0.05; **p < 0.01; ***p < 0.001. (B) Cells were labelled with propidium iodide (PI). Coverslips were washed and mounted on glasses 
and imaged immediately at the fluorescent microscope. Staining was performed in fibroblasts (24 and 48 hours), OVCAR3 (24 hours), MCF10A (48 hours) and MDAMB231 (48 
hours). Cell death was assessed by counting the percentage of PI positive cells and represented in the graphs (% ± SD). Representative images of three independent experiments 
are shown. Significance was considered as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ****p<0.0001. 






Figure 6. RV-loaded-GSH-NSs promote an orchestrated mechanism of cell death that include caspase-dependent and caspase-independent pathways. 
Cells were plated on sterile coverslips and treated with RV-GSH-NSs for the indicated time points: OVCAR3 cells for 24 hours (A) and MDAMB231 cells for 48 hours (B). 
Oxaliplatin was used as positive control, as it promotes cell death. To distinguish whether cell toxicity is associated to apoptosis or necroptosis, two inhibitors were employed: 
Necrostatin-1 (NEC1) and ZVAD, which inhibits primary necrosis and caspase-dependent apoptosis, respectively. Cells (not fixed) were double stained with Annexin V- FITC 
(ANN-V) and propidium iodide (PI) and coverslips were immediately imaged at the fluorescence microscope. Cell death was assessed by counting the percentage of ANN-V 
positive cells, PI positive cells, double positive and negative (living) cells. Data are presented as % ±SD and are reported in tables as well in bar graphs. Significance was considered 
as follows: ****p < 0.0001. All experiments have been reproduced at least three times in independent replicates. 





Figure 7. GSH depletion by BSO strongly hampers the intracellular accumulation of GSH-NSs. (A) Western blotting assessing the intracellular GSH content in 
OVCAR3 and MDAMB231 cells in the absence/presence of buthionine sulfoximine (BSO), an inhibitor of gamma-glutamylcysteine synthetase. For loading control, the 
membranes were re-probed with GAPDH. Graphs represent the densitometric analysis of three independent experiments. Data are presented as average (A.U., arbitrary units) 
±SD. Significance was considered as follows: *p < 0.05; ***p < 0.001. (B-C) Cell were plated on sterile coverslips. Cell internalization studies were performed on OVCAR3 (B) 
and MDAMB231 cells (C) pre-treated or not with BSO and then incubated with C-6-GSH-NSs for 24 hours. Graphs representing the quantification of fluorescence intensity 
(INT.DEN. average per cell) ±SD are shown. Significance was considered as ****p < 0.0001. 
 
GSH depletion prevents RV-GSH-NSs-induced 
toxicity in tumor cells 
Finally, it was necessary to prove that cell 
toxicity induced by RV-GSH-NSs effectively relies on 
the presence of GSH for selective killing of cancer 
cells. Therefore, OVCAR3 and MDAMB231 cancer 
cells were pre-incubated with BSO for 16 hours and 
then exposed to RV- GSH-NSs. At the end, cell 
toxicity was assessed through Cell Tracker and 
propidium iodide staining. Compared to 
BSO-untreated cultures, the cell cultures depleted of 
GSH show a higher number of living cells (Cell 
Tracker positive) and a lower number of death cells 
(PI positive) upon exposure to RV-GSH-NSs (Figure 
8). Taken together, these data demonstrate that GSH 
depletion by BSO results in a marked reduction of 
RV-mediated toxicity in both cancer cell models. 
Discussion 
Nanotheranostics emerge for their potential 
application in biomedical field by combining 
multimodal imaging along with selective targeting 
therapy in the same nanoplatforms [45]. Several 
nanocarriers have been proposed for the construction 
of novel theranostic agents including (i) liposomes 
[46], (ii) dendrimers [23], (iii) mesoporous silica 
nanoparticles [47, 48], (iv) gold nanoparticles [49], (v) 
super paramagnetic iron oxide nanoparticles [50], (vi) 
carbon nanotubes [51], and (vii) quantum dots [23]. 





Figure 8. GSH depletion by BSO prevents RV-mediated toxic effects in both cancer cell models. Cells were plated on sterile coverslips, pre-treated or not with 
BSO and then incubated with RV-GSH-NSs for 24 and 48 hours. (A-B) Cells were labeled with Cell Tracker Blue fluorescent dye. Coverslips were washed and mounted on 
glasses and imaged immediately at the fluorescent microscope. Staining was performed in OVCAR3 (A) and MDAMB231 cells (B). Graphs represent the quantification of 
fluorescence intensity (INT.DEN. average per cell) ± SD. Representative images of three independent experiments are shown. Significance was considered as follows: *p < 0.05; 
**p < 0.01; ****p < 0.0001. (C-D) Cells were stained with propidium iodide (PI). Coverslips were washed and mounted on glasses and imaged immediately at the fluorescent 
microscope. Staining was performed in OVCAR3 (C) and MDAMB231 cells (D). Cell death was assessed by counting the percentage of PI positive cells and represented in the 
graphs (% ± SD). Representative images of three independent experiments are shown. Significance was considered as follows: ***p < 0.001; ****p<0.0001. 
 
Because of their safety and low toxicity, natural 
compounds have gained increasing attention in the 
prevention and treatment of cancer [52]. Resveratrol, a 
naturally occurring polyphenol mainly found in many 
foods, such as mulberry, peanuts, grapes and red 
wine, exhibits chemopreventive and therapeutic 
effects on different cancers by targeting several 
molecules that play important roles in tumorigenesis 
[13]. However, resveratrol exhibits a limited 
pharmacokinetic profile due to its poor bioavailability 
in the systemic circulation, since it is efficiently 
absorbed after oral administration but rapidly and 
extensively metabolized in both animal models and 
humans [53]. 




β-Cyclodextrin-based nanosponges (β-CD-NSs) 
may represent a promising option to enhance the 
therapeutic efficiency and bioavailability of poorly 
soluble molecules [37, 54, 55]. CD-NSs have attracted 
increasing research attention thanks to the 
outstanding properties attributable to their peculiar 
structure. Notably, in addition to the biocompatibility 
typical of polysaccharides, this delivery system is 
characterized by the presence of tunable functional 
groups able to interact with biological tissues, making 
CD-NSs a good tool for targeted drug delivery [56]. 
Recently, our group developed glutathione- 
responsive β-CD-NSs loaded with drugs or imaging 
reporters (GSH-NSs). These innovative nanotools 
have been designed with the aim of selectively 
releasing anti-tumor drugs in cells with a high 
glutathione content, which represents the ideal 
internal stimulus for the rapid destabilization of 
nanocarriers and concomitant drug release within the 
target cells. When used in animals, pharmacokinetic 
and pharmacodynamic studies proved that these NS 
were safe and biodegradable with negligible toxicity, 
while they were efficiently targeted and highly toxic 
to the xenografted tumor [36]. 
Here we report that RV-loaded GSH-NSs 
selectively target and kill cancer cells by promoting 
cell toxicity that involved both apoptosis and 
necroptosis pathways. Additionally, RV can exert its 
anti-cancer activities by promoting autophagy- 
dependent cell death through the involvement of 
lysosomal cathepsin D [12, 14]. Autophagy 
modulation could be exploited for therapeutic 
purposes, since autophagy has been reported to act 
both as an early pro-survival response and as a cell 
death mechanism after a chronic hyperstimulation. 
The differential response elicited depends on the 
genetic/epigenetic and metabolic status of the cancer 
cells targeted, thus underling the need of a critical 
assessment of these features when designing 
theranostics for personalized cancer therapy [40, 57]. 
Further, the benefits promoted by RV include the 
interruption of pro-inflammatory cross-talk occurring 
within the tumor microenvironment [18], the 
inhibition of cancer cell migration [9] and the 
modulation of non-coding RNAs [10]. In addition, RV 
can act as caloric restriction mimetic and could 
substitute for restriction diet by sensitizing cancer 
cells to chemotherapy along with the reduction of 
related side effects [11, 58]. 
Internalization of β-CD-NSs relies on different 
pathways of endocytosis which differs among the cell 
types [59]. Here we found that RV-loaded GSH-NSs 
can target cancer cells regardless of their caveolin-1 
expression. In fact, the NSs were internalized by 
OVCAR3 cells despite the absence of CAV-1 on their 
membrane. This aspect could represent an advantage 
for the application of CD-NSs, since CAV-1 is 
down-regulated in the vast majority of ovarian 
carcinomas [60], and its expression greatly change in 
different type of cancers, depending on tumor staging 
and the tumor microenvironment [61]. On the other 
hand, these NSs could fail entering some tumors (as in 
SKOV3 cells in the present study) and this could 
represent a limitation for its therapeutic application. It 
seems that the redox status of the cell has an impact 
on the efficiency of the endocytosis of the β-CD-NSs, 
yet this process apparently is not dependent on 
caveolin-1. Further investigations are needed to 
address the reason of the differential entry of the 
GSH-responsive β-CD-NSs in the cancer cells. These 
data further outline the importance of assessing more 
in depth the molecular machinery involved in the 
uptake of β-CD-based NSs to support their 
employment in targetable cancers [62]. In order to 
improve internalization, a possible breakthrough 
could be the functionalization of β-CD-NSs on their 
surface, thus allowing for exploitation of the 
specificity of receptor-mediated endocytosis [56]. 
Glutathione tends to be elevated in breast, 
ovarian, head and neck and lung cancers compared to 
the disease-free counterpart tissue, whereas its 
concentration is low in brain and liver tumors. 
Further, cervical, colorectal, gastric and esophageal 
cancers show heterogeneous levels of intracellular 
glutathione depending on the context [63]. Thus, one 
possible weakness of our delivery system is related to 
the high heterogeneity of GSH content, that limits the 
application of these nanocarrier only to the tumors 
highly expressing GSH. 
Interestingly, an increasing number of reports 
indicate that cancer-associated fibroblasts (CAFs) 
display high concentration of glutathione that can be 
released and transferred to cancer cells, pointing out 
that tumor GSH levels are finely-tuned by the 
dynamics occurring in the tumor microenvironment 
[64-67]. Thus, the GSH-responsive delivery of RV 
could be exploited even in the modulation of the 
tumor stroma, allowing for targeting several culprits 
involved in cancer progression and chemoresistance. 
In this regard, next step will be to assess GSH in 
CAFs. Also, we will set a 3D co-culture of cancer cells 
and CAFs and check whether the RV -GSH-NSs can 
target both CAFs and cancer cells and whether it will 
diffuse through the layers and reach the most inner 
portion of the spheroids which mimics the 
microenvironment of the stem cell niche. 
Conclusions 
In conclusion, GSH-NSs were developed to 
improve the solubilization of RV and selective 




targeting to the cancer cells without significant 
toxicity to normal cells. RV release was mediated by 
the intracellular GSH concentration which underlines 
the GSH-responsivity of the nanocarrier. These 
findings suggested that GSH-responsive nanocarrier 
can be used as an innovative tool for selective drug 
targeting in different types of cancers. Overall, our 
data demonstrate that RV-loaded GSH-NSs represent 
a valuable delivery system to target cancer cells by 
exploiting the differential tumor characteristics in 
terms of redox status in parallel with the limitation of 
side effects toward normal cells. In fact, physiological 
level of GSH in normal cells (here represented by skin 
fibroblasts and benign breast epithelial cells) seems 
not sufficient to trigger the release of the drug from 
the nanosponge. 
Highlights 
• Stimuli-responsive nanosponges offer the 
advantage of site-specific drug delivery and 
release; 
• Glutathione responsive nanosponges exploit the 
differential tumor characteristics in terms of 
redox status and limit the side effects toward 
normal cells; 
• Resveratrol-loaded nanosponges are 
preferentially up-taken by cancer cells compared 
to non-tumorigenic cells; 
• Resveratrol-loaded nanosponges selectively kill 
cancer cells. 
Abbreviations 
RV: Resveratrol; β-CD: beta-cyclodextrin; 
PMDA: pyromellitic dianhydride; GSH: Glutathione; 
GSH-NSs: glutathione-responsive nanosponges; BSO: 
buthionine sulfoximine. 
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